1. Home
  2. NGNE vs MPX Comparison

NGNE vs MPX Comparison

Compare NGNE & MPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$18.30

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo Marine Products Corporation

MPX

Marine Products Corporation

HOLD

Current Price

$9.38

Market Cap

319.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
MPX
Founded
2003
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
319.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
MPX
Price
$18.30
$9.38
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$40.14
N/A
AVG Volume (30 Days)
152.7K
20.6K
Earning Date
11-13-2025
02-06-2026
Dividend Yield
N/A
5.93%
EPS Growth
N/A
N/A
EPS
N/A
0.38
Revenue
N/A
$227,666,000.00
Revenue This Year
N/A
$3.97
Revenue Next Year
N/A
$13.02
P/E Ratio
N/A
$24.66
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$7.49
52 Week High
$37.27
$10.08

Technical Indicators

Market Signals
Indicator
NGNE
MPX
Relative Strength Index (RSI) 45.81 55.19
Support Level $18.12 $9.20
Resistance Level $20.44 $9.72
Average True Range (ATR) 1.23 0.34
MACD 0.23 -0.01
Stochastic Oscillator 48.61 67.69

Price Performance

Historical Comparison
NGNE
MPX

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About MPX Marine Products Corporation

Marine Products Corp is a manufacturer of fiberglass motorized boats distributed and marketed through its independent dealer network. The company's only operating segment is Powerboat Manufacturing Business. It operates in the powerboat manufacturing business segment in Nashville, Valdosta, and Georgia. Its product offerings include Chaparral sterndrive, outboard pleasure boats, and Robalo outboard sport fishing boats. The company offers its products to the family recreational markets through its Chaparral brand and to the sportfishing market through its Robalo brand.

Share on Social Networks: